UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

LSD1: biologic roles and therapeutic targeting

Epigenomics, 2016-08, Vol.8 (8), p.1103-1116

2016

Volltextzugriff (PDF)

Enhancer recruitment of a RUNX1, HDAC1 and TLE3 co-repressor complex by mis-expressed FOXC1 blocks differentiation in acute myeloid leukemia

Molecular & cellular oncology, 2021-11, Vol.8 (6), p.2003161-2003161

2021

Volltextzugriff (PDF)

Chronic myelomonocytic leukaemia stem cell transcriptomes anticipate disease morphology and outcome

EBioMedicine, 2020-08, Vol.58, p.102904-102904, Article 102904

2020

Volltextzugriff (PDF)

Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia

Cancer cell, 2006-10, Vol.10 (4), p.257-268

2006

Volltextzugriff (PDF)

NK-2 Homeobox Transcription Factor NKX2-3 Confers Differentiation Block in NPM1-Mutated in Acute Myeloid Leukaemia

Blood, 2023-11, Vol.142 (Supplement 1), p.2759-2759

2023

Volltextzugriff (PDF)

Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy

Nature, 2008-10, Vol.455 (7217), p.1205-1209

2008

Volltextzugriff (PDF)

A stress-responsive enhancer induces dynamic drug resistance in acute myeloid leukemia

The Journal of clinical investigation, 2020-03, Vol.130 (3), p.1217-1232

2020

Volltextzugriff (PDF)

Hierarchical Maintenance of MLL Myeloid Leukemia Stem Cells Employs a Transcriptional Program Shared with Embryonic Rather Than Adult Stem Cells

Cell stem cell, 2009-02, Vol.4 (2), p.129-140

2009

Volltextzugriff (PDF)

The Menin Tumor Suppressor Protein Is an Essential Oncogenic Cofactor for MLL-Associated Leukemogenesis

Cell, 2005-10, Vol.123 (2), p.207-218

2005

Volltextzugriff (PDF)

Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential

Genes & development, 2007-11, Vol.21 (21), p.2762-2774

2007

Volltextzugriff (PDF)

Frequent Derepression of the Mesenchymal Transcription Factor Gene FOXC1 in Acute Myeloid Leukemia

Cancer cell, 2015-09, Vol.28 (3), p.329-342

2015

Volltextzugriff (PDF)

MSC Reprogramming and Aberrant Inflammatory Signaling in Myelofibrosis: Insights from Single-Cell RNA-Sequencing of Trephine Bone Marrow Cells

Blood, 2023-11, Vol.142 (Supplement 1), p.743-743

2023

Volltextzugriff (PDF)

Iadademstat Shows Efficacy in Elderly AML Patients in Combination with Azacitidine. Alice Trial

Blood, 2019-11, Vol.134 (Supplement_1), p.3839-3839

2019

Volltextzugriff (PDF)

Antagonizing Self-Renewal in Acute Myeloid Leukemia: ID2 Takes the Stage

Cancer cell, 2016-07, Vol.30 (1), p.5-7

2016

Volltextzugriff (PDF)

Genome-Wide CRISPR-Cas9 Screen Identifies Sensitizers to LSD1 Inhibition in MLL-Translocated Human AML Cells

Blood, 2018-11, Vol.132 (Supplement 1), p.178-178

2018

Volltextzugriff (PDF)

CCS1477: A Novel Small Molecule Inhibitor of p300/CBP Bromodomain for the Treatment of Acute Myeloid Leukaemia and Multiple Myeloma

Blood, 2019-11, Vol.134 (Supplement_1), p.2560-2560

2019

Volltextzugriff (PDF)

An Open-Label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477, a First in Clinic Inhibitor of the p300/CPB Bromodomains, As Monotherapy in Patients with Advanced Haematological Malignancies

Blood, 2019-11, Vol.134 (Supplement_1), p.1266-1266

2019

Volltextzugriff (PDF)

Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis

Blood, 2019-11, Vol.134 (Supplement_1), p.671-671

2019

Volltextzugriff (PDF)

Elevated plasma 2‐hydroxyglutarate in acute myeloid leukaemia: association with the IDH1 SNP rs11554137 and severe renal impairment

British journal of haematology, 2014-07, Vol.166 (1), p.145-148

2014

Volltextzugriff (PDF)

Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1‐JAK2, BCR‐JAK2 and ETV6‐ABL1 fusion genes

American journal of hematology, 2020-07, Vol.95 (7), p.824-833

2020

Volltextzugriff (PDF)

Chronic myeloid leukemia presenting as compartment syndrome with acute loss of upper limb function

The American journal of emergency medicine, 2021-11, Vol.49, p.273-275

2021

Volltextzugriff (PDF)

Mutant CEBPA: Priming Stem Cells for Myeloid Leukemogenesis

Cell stem cell, 2009-11, Vol.5 (5), p.453-454

2009

Volltextzugriff (PDF)

1 – 23 von 23

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(22)

Publikationsform

Artikel
(23)

Sprache

Englisch
(23)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

LSD1: biologic roles and therapeutic targeting

Enhancer recruitment of a RUNX1, HDAC1 and TLE3 co-repressor complex by mis-expressed FOXC1 blocks differentiation in acute myeloid leukemia

Chronic myelomonocytic leukaemia stem cell transcriptomes anticipate disease morphology and outcome

Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia

NK-2 Homeobox Transcription Factor NKX2-3 Confers Differentiation Block in NPM1-Mutated in Acute Myeloid Leukaemia

Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy

A stress-responsive enhancer induces dynamic drug resistance in acute myeloid leukemia

Hierarchical Maintenance of MLL Myeloid Leukemia Stem Cells Employs a Transcriptional Program Shared with Embryonic Rather Than Adult Stem Cells

The Menin Tumor Suppressor Protein Is an Essential Oncogenic Cofactor for MLL-Associated Leukemogenesis

Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential

Frequent Derepression of the Mesenchymal Transcription Factor Gene FOXC1 in Acute Myeloid Leukemia

MSC Reprogramming and Aberrant Inflammatory Signaling in Myelofibrosis: Insights from Single-Cell RNA-Sequencing of Trephine Bone Marrow Cells

Iadademstat Shows Efficacy in Elderly AML Patients in Combination with Azacitidine. Alice Trial

Antagonizing Self-Renewal in Acute Myeloid Leukemia: ID2 Takes the Stage

Genome-Wide CRISPR-Cas9 Screen Identifies Sensitizers to LSD1 Inhibition in MLL-Translocated Human AML Cells

CCS1477: A Novel Small Molecule Inhibitor of p300/CBP Bromodomain for the Treatment of Acute Myeloid Leukaemia and Multiple Myeloma

Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis

An Open-Label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477, a First in Clinic Inhibitor of the p300/CPB Bromodomains, As Monotherapy in Patients with Advanced Haematological Malignancies

Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis

Elevated plasma 2‐hydroxyglutarate in acute myeloid leukaemia: association with the IDH1 SNP rs11554137 and severe renal impairment

Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1‐JAK2, BCR‐JAK2 and ETV6‐ABL1 fusion genes

Chronic myeloid leukemia presenting as compartment syndrome with acute loss of upper limb function

Mutant CEBPA: Priming Stem Cells for Myeloid Leukemogenesis

Suchergebnisse filtern